Microphysiological head and neck cancer model identifies novel role of lymphatically secreted monocyte migration inhibitory factor in cancer cell migration and metabolism.
Cancer metabolism
Cancer metastasis
Head and neck cancer
Microfluidics
Tumor microenvironment
Journal
Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
27
10
2022
revised:
11
04
2023
accepted:
26
04
2023
pmc-release:
01
07
2024
medline:
24
5
2023
pubmed:
14
5
2023
entrez:
13
5
2023
Statut:
ppublish
Résumé
Regional metastasis of head and neck cancer (HNC) is prevalent (approximately 50% of patients at diagnosis), yet the underlying drivers and mechanisms of lymphatic spread remain unclear. The complex tumor microenvironment (TME) of HNC plays a crucial role in disease maintenance and progression; however, the contribution of the lymphatics remains underexplored. We created a primary patient cell derived microphysiological system that incorporates cancer-associated-fibroblasts from patients with HNC alongside a HNC tumor spheroid and a lymphatic microvessel to create an in vitro TME platform to investigate metastasis. Screening of soluble factor signaling identified novel secretion of macrophage migration inhibitory factor (MIF) by lymphatic endothelial cells conditioned in the TME. Importantly, we also observed patient-to-patient heterogeneity in cancer cell migration similar to the heterogeneity observed in clinical disease. Optical metabolic imaging at the single cell level identified a distinct metabolic profile of migratory versus non-migratory HNC cells in a microenvironment dependent manner. Additionally, we report a unique role of MIF in increasing HNC reliance on glycolysis over oxidative phosphorylation. This multicellular, microfluidic platform expands the tools available to explore HNC biology in vitro through multiple orthogonal outputs and establishes a system with enough resolution to visualize and quantify patient-to-patient heterogeneity.
Identifiants
pubmed: 37178589
pii: S0142-9612(23)00144-8
doi: 10.1016/j.biomaterials.2023.122136
pmc: PMC10205684
mid: NIHMS1898868
pii:
doi:
Substances chimiques
Macrophage Migration-Inhibitory Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
122136Subventions
Organisme : NCI NIH HHS
ID : R01 CA205101
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM140935
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211082
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA278595
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007899
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: David Beebe reports a relationship with BellBrook Labs that includes: equity or stocks. David Beebe reports a relationship with Tasso Inc that includes: equity or stocks. David Beebe reports a relationship with Salus Discovery LLC that includes: equity or stocks. David Beebe reports a relationship with Lynx Biosciences Inc. that includes: equity or stocks. David Beebe reports a relationship with Stacks to the Future LLC that includes: equity or stocks. David Beebe reports a relationship with Flambeau Diagnostics LLC that includes: equity or stocks. David Beebe reports a relationship with Onexio Biosystems LLC that includes: equity or stocks. David Beebe reports a relationship with Abbott Laboratories that includes: consulting or advisory.
Références
Sci Rep. 2020 Apr 21;10(1):6741
pubmed: 32317702
Front Immunol. 2019 Apr 09;10:720
pubmed: 31024552
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19494-9
pubmed: 18042710
Head Neck. 2014 Mar;36(3):385-92
pubmed: 23728942
Clin Cancer Res. 2009 Mar 1;15(5):1585-92
pubmed: 19190133
Biomaterials. 2019 Sep;214:119225
pubmed: 31154151
J Allergy Clin Immunol. 2019 Jan;143(1):104-113.e14
pubmed: 29524537
Lab Chip. 2014 Aug 21;14(16):2941-7
pubmed: 24903648
Eur J Med Res. 2010 Aug 20;15(8):337-44
pubmed: 20947470
Laryngoscope. 2011 Jun;121(6):1202-7
pubmed: 21480280
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
J Biomed Opt. 2022 May;27(5):
pubmed: 35643815
Nat Rev Cancer. 2021 Mar;21(3):162-180
pubmed: 33462499
Int J Mol Med. 2018 Feb;41(2):1062-1068
pubmed: 29207023
J Biomed Sci. 2006 Mar;13(2):159-72
pubmed: 16453176
Lab Chip. 2021 Mar 21;21(6):1139-1149
pubmed: 33533390
Sci Adv. 2022 Jan 21;8(3):eabg6383
pubmed: 35061540
J Biol Chem. 1979 Jun 10;254(11):4764-71
pubmed: 220260
Oncoimmunology. 2018 Dec 12;8(3):1553477
pubmed: 30723584
Sci Rep. 2019 Apr 17;9(1):6199
pubmed: 30996291
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
Drug News Perspect. 2010 May;23(4):257-64
pubmed: 20520854
Cancer Res. 2013 Oct 15;73(20):6164-74
pubmed: 24130112
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Cancers (Basel). 2020 May 06;12(5):
pubmed: 32384738
Int J Oncol. 2010 Mar;36(3):715-23
pubmed: 20126992
Microsc Microanal. 2012 Aug;18(4):761-70
pubmed: 22832200
J Biol Chem. 1980 Jun 10;255(11):5261-3
pubmed: 6102996
Biomed Opt Express. 2017 Apr 03;8(5):2368-2385
pubmed: 28663879
Cell Mol Bioeng. 2020 Oct 13;14(2):133-145
pubmed: 33868496
Head Neck. 2016 Apr;38 Suppl 1:E459-67
pubmed: 25677579
J Biol Chem. 2002 Jul 12;277(28):24976-82
pubmed: 11997397
Cells. 2019 Jun 07;8(6):
pubmed: 31181618
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Oral Oncol. 2018 Dec;87:144-151
pubmed: 30527230
J Biol Chem. 2008 Nov 7;283(45):31183-96
pubmed: 18772142
Cancer. 2013 Nov 15;119(22):4003-11
pubmed: 23963810
Nat Rev Cancer. 2011 Jul 22;11(8):573-87
pubmed: 21779009
Int Rev Cell Mol Biol. 2009;274:1-68
pubmed: 19349035
Pathol Oncol Res. 2017 Apr;23(2):235-244
pubmed: 27771887
Int J Biol Markers. 2010 Apr-Jun;25(2):87-92
pubmed: 20544685
Front Bioeng Biotechnol. 2021 Apr 20;9:644648
pubmed: 33959597
Int J Cancer. 2016 May 1;138(9):2061-6
pubmed: 26355498
Int J Oral Sci. 2010 Mar;2(1):5-14
pubmed: 20690413
Adv Healthc Mater. 2016 Jan 21;5(2):198-204
pubmed: 26610188
Elife. 2022 Feb 24;11:
pubmed: 35200139
Exp Mol Med. 2019 Jan 16;51(1):1-14
pubmed: 30700700
Int J Mol Sci. 2021 Apr 27;22(9):
pubmed: 33925575
Cell Oncol (Dordr). 2020 Oct;43(5):877-888
pubmed: 32488852
FASEB J. 2014 Nov;28(11):4583-90
pubmed: 25077562
Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1271-5
pubmed: 1741380
Cancer Cell Int. 2020 Dec 22;20(1):599
pubmed: 33353547
Oral Oncol. 2019 Apr;91:47-55
pubmed: 30926062
Sci Rep. 2018 Apr 3;8(1):5456
pubmed: 29615678
EBioMedicine. 2021 Nov;73:103634
pubmed: 34673450
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
J Fluoresc. 2004 Sep;14(5):649-54
pubmed: 15617271
Diabetologia. 2008 Nov;51(11):1937-46
pubmed: 18612626
Sci Rep. 2017 Jun 19;7(1):3792
pubmed: 28630487